Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease

Neuroreport. 1994 Mar 21;5(7):747-9. doi: 10.1097/00001756-199403000-00002.

Abstract

Activity of the enzyme which synthesizes acetylcholine, choline acetyltransferase, was estimated in the neocortex of three series of control and demented cases. Clinically demented cases were divided into those with the classical neuropathological features of Alzheimer's disease (numerous neocortical plaques and tangles) and those with Lewy bodies in the brain stem and cortex (together with plaques and variable neurofibrillary pathology). In the Lewy body cases neocortical choline acetyltransferase was consistently lower than in the classical Alzheimer-type cases. Two of the Lewy body cases with extremely low cholinergic activity were responders in therapeutic trials of the cholinesterase inhibitor, tacrine, and the combined data suggest that cholinergic therapy may be particularly relevant to patients with Lewy body type dementia.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / enzymology*
  • Cerebral Cortex / enzymology*
  • Choline O-Acetyltransferase / metabolism*
  • Diagnosis, Differential
  • Humans
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / enzymology*
  • Tacrine / therapeutic use

Substances

  • Tacrine
  • Choline O-Acetyltransferase